10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2012 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 5,962,920 | 4,728,449 | 4,626,172 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 1,363,673 | 1,395,371 | 1,207,450 |
| Amortization of intangible assets | 1,419,534 | 1,648,523 | 1,416,855 |
| Share-based compensation | 433,114 | 382,602 | 387,183 |
| Acquired in-process and collaborations research and development | 288,000 | 672,500 | 313,200 |
| Investing and financing (gains) losses, net | 356,020 | 141,565 | 126,337 |
| Net loss on extinguishment of debt | 1,350,973 | ||
| Trade receivables | 35,996 | (670,152) | (394,665) |
| Inventories | (417,053) | (129,621) | 139,857 |
| Prepaid expenses and other assets | (35,298) | 413,266 | 553,145 |
| Trade accounts payable and other liabilities | (134,209) | 1,789,652 | 572,533 |
| Income taxes | (1,309,269) | (1,402,078) | (212,086) |
| Net Cash From Operating Activities | 9,314,401 | 8,970,077 | 8,735,981 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (1,227,473) | (672,500) | (9,433,243) |
| Acquisitions of property and equipment | (1,795,289) | (1,491,500) | (1,015,075) |
| Purchases of investment securities | (11,997,654) | (5,109,987) | (805,932) |
| Proceeds from sales of investment securities | 8,936,406 | 5,648,720 | 954,361 |
| Release of (deposit of) restricted funds | 1,870,000 | (1,870,000) | |
| Other | 2,722 | 16,099 | (18,426) |
| Net Cash (Used in) From Investing Activities | (6,081,288) | 260,832 | (12,188,315) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 783,868 | (1,964,685) | (203,854) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 14,700,000 | 1,000,000 | 4,000,000 |
| Repayments of long-term debt and debt with maturities over 3 months | (11,071,178) | (3,012,426) | (1,673,998) |
| Purchases of common shares | (2,364,240) | (77,007) | (866,825) |
| Proceeds from stock options exercised, including income tax benefit | 1,850,454 | 968,759 | 328,411 |
| Dividends paid | (3,182,811) | (2,938,096) | (2,671,475) |
| Net Cash From (Used in) Financing Activities | 716,093 | (6,023,455) | (1,087,741) |
| Effect of exchange rate changes on cash and cash equivalents | 40,137 | (43,005) | (620,893) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 3,989,343 | 3,164,449 | (5,160,968) |
| Cash and Cash Equivalents, Beginning of Year | 6,812,820 | 3,648,371 | |
| Cash and Cash Equivalents, End of Year | 10,802,163 | 6,812,820 | 3,648,371 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,366,581 | 1,781,602 | 809,710 |
| Interest paid | 575,895 | 544,559 | 580,168 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |